Cell therapy weekly: largest Phase III trial of an iPSC-derived cell therapy for osteoarthritis begins

This week: a large Phase III trial of an iPSC-derived cell therapy has commenced for osteoarthritis patients; personalized bioprinted scaffolds have been developed for tissue regeneration of ankle joints; an update has been provided for a COVID-19 clinical trial involving Zofin™; and a worldwide agreement has been announced to expand the availability and use of iPSC technology. The news headlines: Largest Phase III trial of an iPSC-derived cell therapy for osteoarthritis has commenced Personalized bioprinted scaffolds developed for tissue regeneration of ankle joints Organicell provides update on Zofin™ clinical trial for COVID-19 Worldwide agreement announced to expand the availability and...